文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

急诊超声引导神经阻滞辅助药物的疗效与安全性:国家超声引导神经阻滞(NURVE)注册研究

Efficacy and Safety of Adjunct Medications in ED Ultrasound-Guided Nerve Blocks: A National Ultrasound-Guided NeRVE (NURVE) Block Registry Study.
PubMed 文献 · Acad Emerg Med · 2025-08-27
一句话结论在11个急诊科的大样本回顾性注册数据中,地塞米松作为局麻药辅助剂与60分钟内疼痛缓解改善相关(OR 1.99),肾上腺素无此关联(OR 0.99),两者均未增加并发症。

该研究分析了国家超声引导神经阻滞(NURVE)注册研究中11个急诊科2022年1月1日至2023年12月31日实施的超声引导神经阻滞数据,评估地塞米松和肾上腺素作为局麻药辅助剂的疗效与安全性。共2742例阻滞中29.6%(812/2742)使用了辅助剂,最常用地塞米松(72.5%,589/812)和肾上腺素(23.5%,191/812)。广义线性混合效应模型显示,地塞米松相比单纯局麻药阻滞获得>50%疼痛缓解的比值比为1.99,肾上腺素为0.99;辅助剂使用与并发症无关联。作者结论认为地塞米松与60分钟内疼痛控制改善相关且无额外安全性担忧,但需前瞻性研究进一步验证。

要点

  • 在11个急诊科的2742例超声引导神经阻滞中,29.6%(812/2742)使用了辅助剂,地塞米松占72.5%(589/812),肾上腺素占23.5%(191/812)。
  • 地塞米松作为辅助剂相比单纯局麻药阻滞,>50%疼痛缓解的比值比为1.99;肾上腺素为0.99。
  • 辅助剂使用与并发症无关联。
  • 作者结论认为地塞米松与60分钟内疼痛控制改善相关,且在该大型回顾性数据集中无额外安全性担忧。
  • 作者指出需前瞻性研究进一步在急诊环境中探究这些发现。

适用人群与场景

  • 2022年1月1日至2023年12月31日在11个急诊科接受超声引导神经阻滞的急诊患者。

研究设计与关键结果

  • 研究类型为回顾性、多中心、观察性注册研究(国家超声引导神经阻滞(NURVE)注册),纳入11个急诊科2022年1月1日至2023年12月31日的数据。
  • 共分析2742例超声引导神经阻滞,其中29.6%(812/2742)使用辅助剂;最常用地塞米松(72.5%,589/812)和肾上腺素(23.5%,191/812)。
  • 采用广义线性混合效应模型(二项分布)比较辅助剂与非辅助剂阻滞,主要结局为疼痛缓解;地塞米松相比单纯局麻药阻滞,>50%疼痛缓解的比值比为1.99;肾上腺素为0.99。
  • 辅助剂使用与并发症无关联。
  • 作者结论:地塞米松与60分钟内疼痛控制改善相关,且在该大型回顾性数据集中无额外安全性担忧。

证据类型、等级与局限

  • 证据类型:回顾性、多中心、观察性注册研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为地塞米松作为急诊超声引导神经阻滞的辅助剂与60分钟内疼痛控制改善相关,且无额外安全性担忧;作者指出需前瞻性研究进一步验证。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Ultrasound-guided nerve blocks (UGNBs) are a core component of multimodal analgesia for acute pain management in emergency departments (EDs). In addition to using standard local anesthetics, adjuncts have been demonstrated to extend the duration of UGNBs. We evaluated the efficacy and safety of dexamethasone and epinephrine as anesthetic adjuncts in UGNBs in the ED.

METHODS: Data were analyzed from the National Ultrasound-guided neRVE (NURVE) Block Registry, a retrospective, multicenter, observational registry evaluating UGNBs performed in 11 EDs from January 1, 2022, to December 31, 2023. A generalized linear mixed effects model (GLMER) with a binomial family examined factors associated with pain reduction when comparing adjunct vs. non-adjunct UGNBs. The dependent variable and primary outcome were pain reduction. Secondary outcomes included safety, dosing of adjuncts, and complications.

RESULTS: A total of 29.6% (812/2742) of UGNBs received adjuncts, most commonly dexamethasone (72.5%, 589/812) and epinephrine (23.5%, 191/812). Dexamethasone had a 1.99 odds ratio of > 50% pain reduction versus isolated local anesthetic blocks, while epinephrine had an odds ratio of 0.99 for > 50% pain reduction. There was no association between adjunct use and complications.

CONCLUSION: Compared to isolated local anesthetic nerve blocks, dexamethasone had an association with improved pain control within 60 min; without additional safety concerns in a large retrospective dataset. Prospective studies are needed to further investigate these findings in the ED setting.

来源:Acad Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Brown J, Milgrim F, Driver L, et al. Efficacy and Safety of Adjunct Medications in ED Ultrasound-Guided Nerve Blocks: A National Ultrasound-Guided NeRVE (NURVE) Block Registry Study. Acad Emerg Med. 2025. PMID: 40873157. doi:10.1111/acem.70128

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。